Mural Oncology plc (MURA)
Mural Oncology plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Dublin, IE. The stock last traded at $2.04, up 0.00% on the session, giving a market capitalisation of $35.4M. On trailing twelve-month figures it carries a trailing P/E of -0.41, a net margin of 0.0%. Its beta of 2.96 implies it has historically moved more than the broad market.
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Mural Oncology plc is most often compared with the following Healthcare names: